Cargando…

Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities

BACKGROUND: To estimate the adjusted conditional overall survival (COS) in patients with esophageal cancer after receiving various treatment modalities via a national population‐based database, and to investigate the possible time‐dependent effects. MATERIALS AND METHODS: Eligible patients diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Wei, Yang, Zhao, Dong, Xin, Yu, Rong, Wang, Weihu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877350/ https://www.ncbi.nlm.nih.gov/pubmed/33314798 http://dx.doi.org/10.1002/cam4.3651

Ejemplares similares

Trends in conditional overall survival of esophageal cancer: a population-based study
por: Deng, Wei, et al.
Publicado: (2021)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study
por: Zhang, Panpan, et al.
Publicado: (2018)

Esophageal abnormalities and the risk for gastroesophageal cancers—a histopathology-register-based study in Sweden
por: Ekheden, Isabella, et al.
Publicado: (2022)

Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma
por: Jiang, Di M., et al.
Publicado: (2020)

Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
por: Kundel, Yulia, et al.
Publicado: (2020)

Esophageal cancer treatment costs by phase of care and treatment modality, 2000‐2013
por: Tramontano, Angela C., et al.
Publicado: (2019)

Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction
por: Bornschein, Jan, et al.
Publicado: (2019)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma
por: Guan, Xin, et al.
Publicado: (2020)

Prognostic significance of NFIA and NFIB in esophageal squamous carcinoma and esophagogastric junction adenocarcinoma
por: Yang, Bo, et al.
Publicado: (2018)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy
por: Cheng, Xingyuan, et al.
Publicado: (2023)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas
por: Ferrer-Torres, Daysha, et al.
Publicado: (2016)

Evolving Management Strategies for Metastatic Esophageal and Gastroesophageal Junction Adenocarcinoma
por: Das, Satya, et al.
Publicado: (2018)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors
por: McGillivray, Erin, et al.
Publicado: (2023)

Cytomegalovirus reactivation in esophageal cancer patients receiving chemoradiotherapy: A retrospective analysis
por: Kitagawa, Koichi, et al.
Publicado: (2021)

Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
por: Deleporte, Amélie, et al.
Publicado: (2021)

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
por: Wood, Anthony C, et al.
Publicado: (2022)

Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival
por: Faluyi, Olusola O., et al.
Publicado: (2017)

Adult nodular lymphocyte‐predominant Hodgkin lymphoma: treatment modality utilization and survival
por: Alonso, Clayton, et al.
Publicado: (2018)

Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy
por: Zhao, Zongxing, et al.
Publicado: (2020)

Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma
por: Liu, Yin-Qiao, et al.
Publicado: (2022)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021)

Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers
por: Kastelowitz, Noah, et al.
Publicado: (2021)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
por: Yoshikawa, Akie Kimura, et al.
Publicado: (2022)

Trends in surgical techniques for the treatment of esophageal and gastroesophageal junction cancer: the 2022 update
por: de Groot, E M, et al.
Publicado: (2023)

Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, L, et al.
Publicado: (2007)

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Incidence and Dosimetric Predictors of Radiation-Induced Gastric Bleeding After Chemoradiation for Esophageal and Gastroesophageal Junction Cancer
por: Montovano, Margaret, et al.
Publicado: (2021)

Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer
por: Xu, Jing, et al.
Publicado: (2019)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study
por: Yuan, Yonggang, et al.
Publicado: (2020)

HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020)

The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
por: van Hootegem, Sander J. M., et al.
Publicado: (2019)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer
por: Ahmad, M. Usman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8t7jsc7sg3ruq6plqdlus2j305